COVID-19 | BioTuesdays

Developments

IBIO-201 demonstrates ability to elicit anti-SARS-CoV-2 immune response in preclinical studies

iBio (NYSE AMERICAN:IBIO) reported initial results from preclinical studies of IBIO-201, one of its two COVID-19 vaccine candidates. IBIO-201 is a subunit vaccine that combines antigens derived from the SARS-CoV-2 spike...

August 10, 2020

Developments

The Hill’s coronavirus report features iBio COVID-19 vaccine candidates and FastPharming System

iBio’s (NYSE AMERICAN:IBIO) two COVID-19 vaccine candidates and FastPharming manufacturing system were featured on The Hill’s coronavirus report on July 30. The company is developing IBIO-200 and IBIO-201, virus-like...

July 30, 2020

Developments

Immunic reports first patients enrolled in Phase 2 COVID-19 trial

The first patients have been enrolled in an investigator-sponsored Phase 2 study evaluating Immunic Therapeutics‘ (NASDAQ:IMUX) IMU-838 for the treatment of COVID-19. IMU-838 is a selective immune modulator that...

July 27, 2020

Developments

Cerecor enrolls first patient in COVID-19 trial

Cerecor (NASDAQ:CERC) enrolled the first patient in its a proof-of-concept trial evaluating CERC-002 in patients with COVID-19 cytokine storm-induced acute respiratory distress syndrome (ARDS). CERC-002 is a...

July 21, 2020

Developments

PhaseBio doses first COVID-19 patient in Phase 2 trial

PhaseBio Pharmaceuticals (NASDAQ:PHAS) dosed the first patient in its potentially pivotal Phase 2 trial evaluating PB1046 for the treatment of high-risk, hospitalized COVID-19 patients. PB1046 is a long-acting analog of...

July 17, 2020

Markets

HCW ups electroCore PT to $2.50 from $1.50

H.C. Wainwright raised its price target for electroCore (NASDAQ:ECOR) to $2.50 from $1.50, citing the FDA’s emergency use authorization of gammaCore, the company’s lead product, to treat COVID-19 patients. The stock...

July 15, 2020

Developments

Rigel Pharma fostamatinib being evaluated in COVID-19 pneumonia trial

Rigel Pharmaceuticals’ (NASDAQ:RIGL) fostamatinib is being evaluated in an investigator-sponsored study for the treatment of COVID-19 pneumonia. Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, is approved...

July 14, 2020

Developments

Akebia vadadustat being evaluated for COVID-19-related acute respiratory distress syndrome

Akebia Therapeutics’ (NASDAQ:AKBA) vadadustat is being evaluated in an investigator-sponsored study as a potential therapy to prevent and lessen the severity of COVID-19-related acute respiratory distress syndrome...

July 14, 2020

Developments

BioSig subsidiary begins enrollment in Phase 2 COVID-19 trial

ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies (NASDAQ: BSGM), began enrolling patients in its Phase 2 clinical trial of merimepodib for the treatment of COVID-19. Merimepodib is an orally...

July 13, 2020

Developments

Bellerophon treats first COVID-19 patient in Phase 3 INOpulse study

Bellerophon Therapeutics (NASDAQ:BLPH) treated the first patient in its Phase 3 study evaluating INOpulse, a pulsed nitric oxide system, for the treatment of COVID-19. The study will enroll up to 500 patients requiring...

July 13, 2020

Developments

FDA authorizes emergency use of electroCore’s vagus nerve stimulation in COVID-19 patients

The FDA has issued an emergency use authorization for electroCore’s (NASDAQ:ECOR) gammaCore Sapphire CV non-invasive vagus nerve stimulation (nVNS) to treat adult patients with known or suspected COVID-19. The FDA has...

July 13, 2020

Developments

Hepion Pharma posts preclinical data supporting two-pronged approach treating COVID-19 with CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that its anti-fibrotic drug candidate, CRV431, was efficacious in two distinct preclinical research models related to COVID-19 disease. CRV431 demonstrated strong anti...

July 7, 2020

Developments

Luminal BioSciences provides guidance on milestones; begins collecting plasma from COVID-19 recovered donors

Liminal BioSciences (NASDAQ, TSX:LMNL) provided a guidance update on the timing of certain expected key milestones for 2020. The company withdrew guidance in May because of the COVID-19 pandemic. In a statement, Kenneth...

July 1, 2020

Developments

Texas A&M video series features iBio COVID-19 vaccines

iBio’s (NYSE American:IBIO) two COVID-19 vaccine candidates were featured on the final episode of the video series, “COVID-19: The Texas A&M University System Responds.” “This is an important collaboration,” John...

June 26, 2020

Developments

Kamada IgG therapy cleared for compassionate COVID-19 use in Israel

Kamada (NASDAQ, TASE:KMDA) completed manufacturing of the first batch of its plasma-derived immunoglobulin (IgG) product for the treatment of COVID-19 and the initial vials are available for compassionate use in Israel...

June 17, 2020

Developments

PharmAust lab tests show positive signs for suppressing COVID-19

PharmAust (ASX:PAA) posted positive preliminary results in experiments aimed at inhibiting the virus that causes COVID-19. PharmAust, which traditionally is focused on repurposing existing drugs for cancer therapy, is...

June 4, 2020

Developments

iBio initiates second COVID-19 vaccine program

iBio (NYSE AMERICAN:IBIO) initiated preclinical immunization studies for its second COVID-19 vaccine platform with the potential for rapid manufacturing scale-up at its FastPharming System. The new subunit vaccine, IBIO...

June 4, 2020

Markets

BTIG starts Fulgent Genetics at buy; PT $20

BTIG initiated coverage of Fulgent Genetics (NASDAQ:FLGT) with a “buy” rating and $20 price target. The stock closed at $16.06 on May 28. Fulgent is a genetic testing service provider that has delivered more than...

May 29, 2020

Markets

Dawson James starts Sorrento Therapeutics at buy; PT $24

Dawson James Securities launched coverage of Sorrento Therapeutics (NASDAQ:SRNE) with a “buy” rating and $24 price target. The stock closed at $5.07 on May 22. Analyst Jason Kolbert writes that Sorrento’s STI-1499...

May 26, 2020

Developments

Maxim ups Co-Diagnostics to buy; PT $30

Maxim Group upgraded Co-Diagnostics (NASDAQ:CODX) to “buy” from “hold” with a $30 price target, saying that COVID-19 testing has been transformative for the company. The stock closed at $18.85 on May 19. Co-Diagnostics...

May 20, 2020

Developments

PharmaJet partners with Abnova to develop needle-free COVID-19 vaccine

Closely-held PharmaJet’s needle-free injection system will be used to deliver a SARS-CoV mRNA vaccine being developed by Abnova, the world’s largest antibody vaccine manufacturer. “Our system has been found to improve...

May 19, 2020

Features

Spring Bank Pharma may expand R&D with potential COVID-19 agents

After abruptly ending its hepatitis B virus program in January, Spring Bank Pharmaceuticals (NASDAQ:SBPH) is in the early stages of examining whether its family of RIG-I agonists have the potential to attack SARS-CoV-2...

May 19, 2020

IBIO-201 demonstrates ability to elicit anti-SARS-CoV-2 immune response in preclinical studies

The Hill’s coronavirus report features iBio COVID-19 vaccine candidates and FastPharming System

Immunic reports first patients enrolled in Phase 2 COVID-19 trial

Cerecor enrolls first patient in COVID-19 trial

PhaseBio doses first COVID-19 patient in Phase 2 trial

HCW ups electroCore PT to $2.50 from $1.50

Rigel Pharma fostamatinib being evaluated in COVID-19 pneumonia trial

Akebia vadadustat being evaluated for COVID-19-related acute respiratory distress syndrome

BioSig subsidiary begins enrollment in Phase 2 COVID-19 trial

Bellerophon treats first COVID-19 patient in Phase 3 INOpulse study

FDA authorizes emergency use of electroCore’s vagus nerve stimulation in COVID-19 patients

Hepion Pharma posts preclinical data supporting two-pronged approach treating COVID-19 with CRV431

Luminal BioSciences provides guidance on milestones; begins collecting plasma from COVID-19 recovered donors

Texas A&M video series features iBio COVID-19 vaccines

Kamada IgG therapy cleared for compassionate COVID-19 use in Israel

PharmAust lab tests show positive signs for suppressing COVID-19

iBio initiates second COVID-19 vaccine program

BTIG starts Fulgent Genetics at buy; PT $20

Dawson James starts Sorrento Therapeutics at buy; PT $24

Maxim ups Co-Diagnostics to buy; PT $30

PharmaJet partners with Abnova to develop needle-free COVID-19 vaccine

Spring Bank Pharma may expand R&D with potential COVID-19 agents

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter